IM Cannabis Corp. (NASDAQ:IMCC – Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 36,121 shares, a decrease of 51.6% from the September 30th total of 74,661 shares. Based on an average daily volume of 121,192 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.6% of the shares of the company are sold short.
Analyst Ratings Changes
Several equities analysts have weighed in on IMCC shares. Wall Street Zen lowered IM Cannabis to a “strong sell” rating in a research note on Saturday, October 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of IM Cannabis in a report on Monday, October 19th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has an average rating of “Sell”.
Get Our Latest Stock Analysis on IM Cannabis
IM Cannabis Stock Performance
IM Cannabis (NASDAQ:IMCC – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter. The business had revenue of $5.34 million for the quarter.
IM Cannabis Company Profile
IM Cannabis Corp. (NASDAQ: IMCC) is a medical cannabis company focused primarily on the Israeli and German markets. The company develops, sources, imports, distributes and markets medical cannabis products under the IMC brand, serving patients through pharmacies, clinics and other authorized channels.
In Israel, IM Cannabis is involved in the supply of medical cannabis products, including flower and other cannabis-based offerings, through affiliated cultivation, processing and distribution operations.
Featured Articles
- Five stocks we like better than IM Cannabis
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
